Torrent Pharma Reports Positive Financial Performance in Q2 FY25
Torrent Pharmaceuticals, a leading player in the pharmaceuticals and drugs industry, has recently announced its financial results for the quarter ending September 2024. The company has received a ‘Hold’ call from MarketsMOJO, indicating a neutral stance on its stock.
Despite a slight decrease in its overall score from 24 to 15 in the last three months, Torrent Pharma has shown positive financial performance in the quarter. One of the key factors contributing to this is the company’s high operating profit to interest ratio, which has been consistently growing over the past five quarters. This indicates an improvement in the company’s ability to manage its interest payments.
Moreover, Torrent Pharma has also seen a significant increase in its operating cash flow, with the highest amount of Rs 3,266.08 crore generated in the last three years. This reflects the company’s strong revenue generation from its business operations.
In terms of sales, Torrent Pharma has recorded its highest quarterly net sales of Rs 2,889.00 crore, with a consistent growth trend over the past five quarters. This indicates a positive outlook for the company’s near-term sales performance.
Additionally, the company’s operating profit and profit before tax have also shown a consistent growth trend over the past five quarters, with the highest figures of Rs 939.00 crore and Rs 677.00 crore respectively. This reflects a positive trend in the company’s near-term operating profit and profit before tax.
Furthermore, Torrent Pharma has also recorded a 29.31% year-on-year growth in its profit after tax for the nine-month period, with a positive trend in its near-term PAT performance.
Overall, Torrent Pharmaceuticals has shown a strong financial performance in the quarter ending September 2024, with improvements in key areas such as operating profit, sales, and profit after tax. With a high operating profit margin of 32.50%, the company’s efficiency has also improved, making it a promising player in the pharmaceuticals and drugs industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
{{text.big_txt}}
{{text .small_txt}}
{{dashverdictresult.dashboard.stock_details.short_name}}
SEND BY EMAIL
Register now to see if the stock’s characteristics match your investment style
Subscribe now to see if the stock's characteristics match your investment style
{{dashverdictresult.dashboard.risk_return_voltality.risk_type}}, {{dashverdictresult.dashboard.risk_return_voltality.return_type}}
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
Create your portfolio and know how much should this stock be in your portfolio
Subscribe now to know how much you should hold in this stock
We have found 2 better stocks that you can consider
{{dashverdictresult.dashboard.return_text}}
Investors Returns (3 years) –
| Period | 6M | 1Y | 2Y | 3Y |
| {{ keyd.val }} | ||||
| {{ keyd.val }} |
Quality: {{dashverdictresult.dashboard.dotsummary.q_txt}}
Valuation: {{dashverdictresult.dashboard.dotsummary.v_txt}}
Quarterly Financial Trend: {{dashverdictresult.dashboard.dotsummary.f_txt}}
Technicals: {{dashverdictresult.dashboard.dotsummary.tech_txt}}
Stock Info:
BSE – {{dashverdictresult.dashboard.stock_details.scripcode}}/ NSE – {{dashverdictresult.dashboard.stock_details.symbol}}
Market Cap – {{dashverdictresult.dashboard.priceinfo.mcap_class}} (Rs. {{dashverdictresult.dashboard.priceinfo.mcap| number :0}} cr)
Sector – {{dashverdictresult.dashboard.stock_details.ind_name}}
52 w H/L (Rs.) – {{dashverdictresult.dashboard.priceinfo.wk_high52}}/{{dashverdictresult.dashboard.priceinfo.wk_low52}}
Average vol (6M) – {{dashverdictresult.dashboard.priceinfo.vol}}
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
